Detalles de la búsqueda
1.
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Lancet Oncol
; 21(9): 1173-1187, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32758455
2.
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
BMC Cancer
; 17(1): 646, 2017 Sep 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28899363
3.
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
Lancet Oncol
; 14(3): 249-56, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23414587
4.
Expression of ADAM9 in CIN3 lesions and squamous cell carcinomas of the cervix.
Gynecol Oncol
; 114(2): 332-6, 2009 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-19473694
5.
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma.
Oncotarget
; 10(19): 1850-1859, 2019 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30956763
6.
Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study.
Lancet Haematol
; 4(8): e350-e361, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28712941
7.
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
Clin Cancer Res
; 21(4): 730-8, 2015 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25500057
8.
The impact of progesterone on simultaneous, local secretion of IGFBP-3 and IGF-I [IGFBP-3/IGF-I index] by human malignant and non-malignant breast explants depends on tissue steroid receptor phenotype.
Ginekol Pol
; 74(9): 767-74, 2003 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-14674122
9.
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.
J Clin Oncol
; 31(20): 2586-92, 2013 07 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-23733761
10.
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
J Clin Oncol
; 29(15): 2011-9, 2011 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-21502544
11.
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
J Clin Oncol
; 27(5): 663-71, 2009 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-19114683
12.
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
J Clin Oncol
; 26(14): 2311-9, 2008 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-18390971
Resultados
1 -
12
de 12
1
Próxima >
>>